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ratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, CanadaIntroduction: Atypical hemolytic uremic syndrome is a thrombotic microangiopathy, which is linked to
hereditary or autoimmune defects in complement activators or regulators present in blood and on
vascular endothelial cells. Acute thrombotic microangiopathy episodes are typically preceded by in-
fections, which by themselves would not be expected to manifest HUS. Thus, it is possible that the host
immune response contributes to the precipitation of aHUS. However, the mechanisms involved are not
fully understood. We hypothesized that neutrophils trigger aHUS via initiating platelet aggregate forma-
tion on complement-activated endothelial cells.
Methods: We investigated neutrophil adhesion to complement-activated endothelial cells under static and
ﬂow conditions in vitro and ex vivo.
Results: Our results show that complement activation on endothelial cells promotes neutrophil adhesion,
which is signiﬁcantly reduced when the complement terminal pathway is blocked. When neutrophils
and platelets are perfused simultaneously, neutrophils adhering to endothelial cells also induce the for-
mation of platelet-neutrophil aggregates on these cells. Sera from patients with aHUS recapitulated these
results.
Discussion: Therefore, our ﬁndings of (i) neutrophils adhering to complement-activated endothelial cells,
(ii) the formation of neutrophil-platelet aggregates on endothelial cells, and (iii) the ability of aHUS serum
to induce similar effects identify a possible role for neutrophils in aHUS manifestation.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T hrombotic microangiopathy (TMA) is characterizedby endothelial cell (EC) activation and/or injury and
subsequent thrombus formation in themicrovasculature,
especially of the kidney glomeruli.1 TMA can manifest
in the context of a broad spectrum of conditions
involving the classical and/or alternative pathways of
complement.1 Complement activation is physiologically
inhibited on the surface of the vascular endothelium by
plasma-borne and EC surface-bound regulators. These
include the soluble complement factor H (CFH), whichspondence: Christoph Licht, Division of Nephrology, The
tal for Sick Children, 555 University Avenue, Toronto,
io M5G 1X8, Canada. E-mail: christoph.licht@sickkids.ca
ved 5 April 2016; revised 23 July 2016; accepted 15 August
published online 30 August 2016is dysfunctional in a signiﬁcant portion of patients
with atypical hemolytic uremic syndrome (aHUS), and
membrane cofactor protein/CD46, decay-accelerating
factor/CD55, and protectin/CD59 with the latter inhib-
iting the formation of the membrane attack complex
(MAC; C5b-9).2–4 Loss of complement regulation on
vascular ECs results in enhanced C3b deposition and
MAC formation, inducing a proinﬂammatory phenotype
and eventually clot formation.5,6
Manifestation of aHUS is highly variable in terms of
ﬁrst presentation, severity of clinical presentation, and
risk of recurrence.1,7,8 Initial TMAonset and subsequent
acute episodes (ﬂare-ups) are often preceded by in-
fections, pointing to a critical role for inﬂammatory
triggers and/or immune responses in manifestation of
aHUS.7 Complement and neutrophils play major roles inKidney International Reports (2017) 2, 66–75
Table 1. Summary of diagnostic work-up and treatment of patients
with aHUS whose serum was used for neutrophil adhesion studies
Patient no. Genetics CFH Abs Treatment
1 Not tested Positive None









4 CFHR-3/CFHR-1—homozygous deletion Positive Eculizumab
5 C3—homozygous variant of unknown signiﬁcance
(c.304C>G [p.Arg102Gly])
Negative Eculizumab
Eculizumab treatment followed a weight- and/or age-based standard protocol.
aHUS, atypical hemolytic uremic syndrome; CFH Abs, CFH autoantibodies; DEAP HUS,
deﬁciency of complement factor H-related (CFHR) proteins and CFH autoantibody-
positive hemolytic uremic syndrome.
M Riedl et al.: Complement and Neutrophils on Endothelial Cells TRANSLATIONAL RESEARCHimmune defense and have the potential for mutual
activation.9,10 Although a role for neutrophils in trig-
gering TMA in the context of complement dysregulation
has not been established, neutrophil inﬁltration has been
observed in biopsies of patients with TMA11,12 (and
personal unpublished observation). In this study, we
examined whether complement activation can induce
neutrophil adhesion and subsequent platelet aggregate
formation on complement-activated ECs.
CONCISE METHODS
Patients
Ethics approval was obtained from the Research Ethics
Board at The Hospital for Sick Children, Toronto,
Ontario. A signed consent was obtained from all pa-
tients and/or their parents, respectively.
Blood Outgrowth Endothelial Cell Culture and
Preparation of Neutrophils and Platelets
Blood outgrowth endothelial cells (BOECs) were ob-
tained from healthy controls and cultured in Endothelial
Basal Medium 2 (Lonza, Walkersville, MD) supple-
mented with Endothelial Cell Growth Medium (EGM-2
BulletKit; Lonza Walkersville Inc., Walkersville, MD),
10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO),
and 5% antibiotic-antimycotic mix (Sigma).13 Neutro-
phils were isolated from whole blood as described.14 In
short, neutrophils were isolated using Polymorphprep
(Axis-Shield, Dundee, Scotland), erythrocytes were
lysed, and washed neutrophils were resuspended
in Roswell Park Memorial Institute 1640 medium
(WISENT, St Bruno, QC, Canada) containing 10 mM
N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid
(Gibco, Life Technologies, Carlsbad, CA). Platelets were
isolated from same donors as described.15 In short,
whole blood was drawn in acid citrate dextrose (1:7)
tubes and after centrifugation platelet-rich plasma was
isolated and washed twice with phosphate-buffered
saline/acid citrate dextrose.
Complement Activation on Cultured ECs
Complement activation on BOECs was achieved via a
method previously established by us13 and others.16
Brieﬂy, BOECs were incubated with antibodies block-
ing the surface complement regulators CD46, CD55, and
CD59 using the monoclonal mouse anti-human anti-
bodies GB24 (IgG1, kindly provided by John Atkinson,
St. Louis, MO),17,18 BRIC216 (IgG1), and BRIC229
(IgG2b, both from International Blood Group Reference
Laboratory, NHS Blood and Transplant, Bristol, UK),
respectively,19 at a concentration of 5 mg/ml. Normal
human serum (NHS) prepared from whole blood of
adult donors was used as a source of complement fac-
tors. Complement-inactivated serum was prepared byKidney International Reports (2017) 2, 66–75heating (heat-inactivated serum [HUS])20 or exhaustion
with cobra venom factor (1 U/ml at 37C for 90 mi-
nutes, Quidel, San Diego, CA). Speciﬁc inactivation of
the complement cascade was achieved using C3-, C5-,
and C6-depleted serum (Complement Technology,
Tyler, TX). The rabbit erythrocyte lysis assay was used
to conﬁrm complement inactivation.21
Patients With aHUS
Serum from patients with aHUS due to CFH mutation
(n ¼ 2), CFH autoantibodies (n ¼ 1), and C3 mutation
(n¼1) was taken from the biorepository of our KidCOM
study (www.kidcom.ca) and was used without prior
blockade of complement regulators. Detailed informa-
tion in particular on the complement status of these
patients is presented in Table 1.
Neutrophil Adhesion to BOECs Under Static
Conditions
BOECs were grown to conﬂuence overnight in a 96-well
enzyme-linked immunosorbent assay plate (Sarstedt,
Nümbrecht, Germany), exposed to anti-CD46/CD55/
CD59 and 50% NHS for 1 hour or tumor necrosis
factor-a (20 ng/ml) for 4 hours. Serum was washed
off and 100 ml of 1  106/ml calcein-labeled
neutrophils in Roswell Park Memorial Institute/N-2-
hydroxyethylpiperazine-N0-2-ethanesulfonic acid was
added for 30 minutes. As previously described, non-
adherent cells were removed by centrifugation of the
96-well plate upside down at 100  g for 1 minute.22
Neutrophil adhesion was quantiﬁed using a ﬂuores-
cent plate reader at excitation and emission wave-
lengths of 494 and 517 nm, respectively.
Neutrophil and Platelet Adhesion to BOECs
Under Flow Conditions
Neutrophils and platelets were exposed to BOECs
under ﬂow conditions using a Bioﬂux microﬂuidic
system (Fluxion Biosciences, South San Francisco, CA)67
TRANSLATIONAL RESEARCH M Riedl et al.: Complement and Neutrophils on Endothelial Cellsas previously described.22 Brieﬂy, the recording
channels of 48-well (0–20 dyne/cm2) Bioﬂux plates
were coated with 0.05 mg/ml of rat-tail collagen type I
in 0.02 M acetic acid before the introduction of BOECs,
which were grown to conﬂuence, washed, and exposed
to blocking antibodies for 30 minutes. Calcein-labeled
(2.5 mM, Life Technologies) neutrophils were per-
fused simultaneously with 50% serum (NHS, heat-
inactivated serum, C5-depleted serum, C6-depleted
serum, patient serum) at a ﬂow rate of 1 dyne/cm2,
and images and video were obtained after 5 minutes
using a 4 objective on a Nikon Ti epiﬂuorescence
microscope using a Qimaging CCD camera and NIS
software. Neutrophil adhesion was quantiﬁed via total
green ﬂuorescence intensity within the measurement
channel, obtained via the Bioﬂux software or counted.
For double adhesion experiments, platelets (600  106/
ml) and neutrophils (12  106/ml) in RPMI-1640/
HEPES were mixed with NHS at a ratio of
1:1:2, whereas the control channel was loaded with
RPMI-1640/HEPES NHS-containing platelets but no
neutrophils.
Flow Cytometry Analysis of Neutrophil
Activation
Neutrophils (0.5  106/ml) were incubated with
various types of treatment (calcein 2.5 mM; TNF-a 20
ng/ml) for 30 minutes, washed with phosphate-
buffered saline, and incubated with 5 ml of Alexa 647
anti-human CD11b antibody (Biolegend, San Diego, CA)
for 30 minutes and a ﬁxable viability dye eFluor 780
(eBioscience, Affymetrix, Santa Clara, CA). At least
10,000 events were recorded using the Attune Acoustic
Focusing Cytometer (Life Technologies) and analyzed
using FlowJo software. Results are given as median
ﬂuorescence intensity. Cells were gated for live cells
(red laser 536 nm, emission channel 2) and forward and
side scatter. CD11b was recorded via the red laser 536
nm/emission channel 1, and calcein on the blue laser
488 nm/emission channel 1. To correct for spectral
overlap during multicolor ﬂow cytometry experiments,
color compensation was performed each time.
RESULTS
Complement Activation on BOECs Causes
Neutrophil Adhesion
To determine whether neutrophils adhere to ECs, we
isolated human neutrophils and allowed them to
interact with BOECs from healthy donors under
various complement-activating conditions. As recently
described in detail, complement activation on BOECs
was achieved by preincubation of BOECs with anti-
bodies against CD59, or the combination of antibodies68against membrane-anchored complement regulators
CD46, CD55, and CD59 with 50% NHS as a source of
complement.13
Endothelial adhesion of calcein-stained neutrophils
was examined under both static and microﬂuidic
conditions. We conﬁrmed that calcein staining per se
did not activate neutrophils (Supplementary
Figure S1). Under static conditions, complement acti-
vation resulted in neutrophil adhesion to ECs subse-
quent to complement ﬁxation. The number of
neutrophils adhering to ECs subsequent to complement
activation was comparable to that achieved in ECs
stimulated with TNF-a (Figure 1a). Of note, no
neutrophil adhesion occurred when non-complement
ﬁxing antibodies were used alone (e.g., anti-CD46 or
anti-CD55 antibodies; data not shown). Similar results
were obtained in microﬂuidic conditions (Figure 1b–d).
When neutrophils were perfused over ECs in a
microﬂuidic chamber at a rate of 1 dyne/cm2, pre-
treatment with CD59 antibody alone or—to a higher
extent—with the combination of CD46, CD55, and
CD59 antibodies resulted in enhanced neutrophil
adhesion. Neutrophil adhesion was higher when NHS
was co-perfused with neutrophils as compared with
pretreatment of cells with NHS for 60 minutes
(Figure 1b). Perfused neutrophils adhered to
complement-activated ECs within 2 minutes and im-
ages were taken after 5 minutes (Figure 1c and d,
Supplementary Videos S1–S3). For all future experi-
ments, neutrophils were co-perfused with NHS.Neutrophil Adhesion Is Complement-Mediated
and Terminal Pathway Dependent
Neutrophil adhesion to BOECs was abolished when
complement inactive serum (HIS) was used (Figure 2a
and b, Supplementary Video S1). The same effect was
achieved by the pretreatment of serum with cobra
venom factor (Figure 2b, images not shown). Cobra
venom factor is a potent activator of the C3 and C5
convertases and renders sera complement inactive
within 90 minutes via depleting active complement
components.23 Preventing terminal pathway activation
by using serum depleted of C3 (Figure 2c and d), C5
(Figure 2e and f, Supplementary Video S2), or C6
(Figure 2f, images not shown), neutrophil adhesion was
signiﬁcantly reduced. This was seen when BOECs were
pretreated with anti-CD59 antibody alone (Figure 2a, c,
and e) or the combination of anti-CD46, CD55, and
CD59 antibodies (Supplementary Figure S2). A hemo-
lysis assay with rabbit erythrocytes was used to
conﬁrm that complement depletion (heat-inactivated
serum, cobra venom factor, or C3-/C5-/C6-depleted
sera) was successful (data not shown).24Kidney International Reports (2017) 2, 66–75
Figure 1. Neutrophil adhesion to complement-challenged BOECs under static and dynamic conditions. (a) BOECs cultured as monolayers in 96-
well plates were treated with 50% NHS with or without prior incubation with anti-CD46, -CD55, and -CD59 antibodies. Cells incubated for 4 hours
with TNF-a 20 ng/ml served as positive control. Calcein-labeled neutrophils were introduced for 30 minutes and then removed before wells were
read for green fluorescence emission. Total fluorescence was normalized to values obtained for BOECs incubated with media only; n¼ 5, **P <
0.01 (1-way ANOVA with Dunnett’s multiple comparison test). (b–d) Calcein-labeled neutrophils were perfused over BOECs in a Bioflux chamber.
(b) Markedly enhanced neutrophil adhesion was observed when neutrophils were co-perfused with 50% NHS for 5 minutes compared with
preincubation with 50% NHS for 1 hour and then subsequent exposure to neutrophils (2-tailed t-test). (c) Calcein-labeled neutrophils perfused in
a Bioflux system at 1 dyne/cm2 with 50% NHS over untreated BOECs (top channel) or cells incubated with anti-CD46, -CD55, and -CD59 an-
tibodies (bottom channel) showed marked adhesion after 5 minutes to cells with combined complement regulator blockade. (d) Quantification of
neutrophil adhesion to BOECs within the measurement channel via total green fluorescence intensity shows the effect of various complement
activation conditions, with combined incubation with anti-CD46, -CD55, and -CD59 antibodies showing significant neutrophil adhesion (n ¼ 3–8,
*P < 0.05, ***P < 0.001; 1-way ANOVA with Dunnett’s multiple comparison test). ANOVA, analysis of variance; BOECs, blood outgrowth
endothelial cells; NHS, normal human serum; TNF-a, tumor necrosis factor-a.
M Riedl et al.: Complement and Neutrophils on Endothelial Cells TRANSLATIONAL RESEARCHTaken together, these results (Figures 1 and 2) indicate
that neutrophil adhesion to ECs is complement-mediated
and terminal pathway dependent.
Sera From Patients With aHUS Result in
Neutrophil Adhesion to BOECs in a Microﬂuidic
Chamber
Furthermore, we were interested to examine if
neutrophil adhesion to ECs can be observed when
serum from patients with aHUS is used. Sera were
taken from 5 patients with aHUS (patients 1–5; Table 1)
in clinical remission (i.e., normal platelet count, no
hemolysis, and normal kidney function). Genetic and
biochemical work-up identiﬁed CFH autoantibodiesKidney International Reports (2017) 2, 66–75in patient 1 (no genetic testing performed), a he-
terozygous CFH variant in patient 2 (c.3644G>A
[p.Arg1215Gln]), deﬁciency of complement factor
H-related (CFHR) proteins and CFH autoantibody-
positive HUS25 with CFHR-3/CFHR-1 deletion and
CFH autoantibodies in patients 3 and 4 in which patient
3 was combined with a disease causing CFH mutation
(c.3148A>T [p.Asn1050Tyr]), and a homozygous C3
variant (c.304C>G [p.Arg102Gly]) in patient 5. Perfu-
sion of serum from all patients with aHUS caused an up
to 6-fold increase in neutrophil adhesion to ECs when
compared with control serum (Figure 3). In keeping
with a predominant role of the terminal complement
pathway in neutrophil adhesion to ECs, neutrophil69
Figure 2. Complement blockade at the level of C3 and C5 decreases neutrophil adhesion to BOECs. (a,b) Neutrophil adhesion to BOECs with
anti-CD59 antibody incubation dropped to background levels in the presence of serum depleted of complement activity by heat-inactivated
serum (HIS); results are summarized in (b) including cobra venom factor (CVF). (c,d) Neutrophil adhesion was also reduced relative to NHS
when C3-depleted serum was used; results are summarized in (d). (e,f) Neutrophil adhesion was decreased relative to NHS when C5-depleted
serum was used; results are summarized in (f) including C6-depleted serum. Fluorescence intensity in (b), (d), and (e) is normalized to the value
obtained for 50% NHS in each experiment, n ¼ 3–6; ***P < 0.001, ****P < 0.0001 (2-way ANOVA with Dunnett’s multiple comparison test, or
unpaired t-test with Welch’s correction in Figure 2d). Bar ¼ 50 mm. ANOVA, analysis of variance; BOECs, blood outgrowth endothelial cells;
NHS, normal human serum; PMNs, polymorphonuclear leukocytes.
TRANSLATIONAL RESEARCH M Riedl et al.: Complement and Neutrophils on Endothelial Cellsadhesion was reduced to a minimum when using serum
of the 2 patients (patients 4 and 5) treated with the C5
antibody eculizumab, which blocks the terminal com-
plement pathway.
Complement Fixation on ECs Causes
Platelet-Neutrophil Aggregation
The functional consequences of neutrophil adhesion to
ECs were further investigated by introducing platelets70in the microﬂuidic chamber. Perfusion of platelets with
50% NHS after pretreatment with CD46, CD55, and
CD59 antibodies resulted in adhesion of a moderate
number of platelets on activated ECs without the for-
mation of obvious platelet aggregates.13 However,
simultaneous perfusion of neutrophils (3  106/ml)
and platelets (150  106/ml) in 50% NHS over
pretreated ECs resulted in neutrophil adhesion
and the subsequent formation of neutrophil-plateletKidney International Reports (2017) 2, 66–75
Figure 3. Serum from patients with aHUS results in neutrophil
adhesion to BOECs. BOECs cultured in the BioFlux microperfusion
chamber were exposed to 50% serum from patients with aHUS in
clinical remission (see Table 1 for details) and calcein-labeled
neutrophils at 1 dyne/cm2. Number of adhering neutrophils was
counted per high power field (hpf) and ratio over adhering neutro-
phils incubated with control serum was calculated. n ¼ 4 for all
patients except patient 3. aHUS, atypical hemolytic uremic syn-
drome; BOECs, blood outgrowth endothelial cells.
M Riedl et al.: Complement and Neutrophils on Endothelial Cells TRANSLATIONAL RESEARCHaggregates. These aggregates increased in size over
the entire observation period of 40 minutes (Figure 4,
Supplementary Video S3). Our results suggest that in
the presence of platelets complement-mediated neu-
trophil adhesion to ECs induces the formation of
neutrophil-platelet aggregates beginning as micro-
aggregates and evolving into larger aggregates.
DISCUSSION
TMA is characterized by thrombus formation in
the microvasculature, predominantly of the kidney
glomeruli. TMA can occur as primary or secondary
disease, and TMA pathogenesis is regulated by different
mechanisms.1,26 Recently, complement dysregulation
on ECs—caused by genetic or autoimmune defects—has
been identiﬁed as the cause for aHUS,4,27 and the com-
plement system has consequently gained a prominent
role as treatment target for this clinical condition.28,29 Of
note, complement defects and complement-targeting
treatments are also increasingly recognized as relevant
to different types of TMA (reviewed in Riedl et al.1),
a development highlighting the existence of a
complement-based TMA spectrum. Our ﬁndings further
the understanding of complement-mediated TMA pa-
thology by reconciling the relevance of infection and
the potential role of host immune components, partic-
ularly neutrophils, in aHUS pathogenesis.
The common ﬁnding of preceding infections in pa-
tients with TMA either at ﬁrst presentation or during
ﬂare-ups7,8 and studies linking complement activation
with a proinﬂammatory phenotype (i.e., neutrophil
activation)5,6,9,30 highlight an important yet poorlyKidney International Reports (2017) 2, 66–75understood role for neutrophils in TMA pathogenesis.
Although previously only speculated upon,9 our re-
sults demonstrate that neutrophil adhesion is caused by
complement—in particular, MAC/C5b-9—deposition
on ECs, and that complement-mediated neutrophil
adhesion to ECs facilitates platelet adhesion and the
formation of platelet-neutrophil aggregates.
Camous et al.9 linked the complement and inﬂam-
matory systems further by showing that activation of
neutrophils via cytokines results in complement acti-
vation on neutrophils, thus engaging a positive feed-
back loop with further activation of neutrophils. In
keeping with this concept, we observed neutrophil
adhesion to ECs to occur rapidly (within 2 minutes) after
complement activation. Our results, however, point
toward a different mechanism. Whereas the studies by
Camous et al. highlight a signiﬁcant role for C5a/C5a
receptor interaction, our results identify a key role for
the terminal complement pathway and the formation of
MAC/C5b-9, as neutrophil adhesion to ECs was not
different between the use of C3-, C5-, and C6-depleted
serum with the ﬁrst 2 conditions preventing the gen-
eration of C3a and C5a and blocking the induction of the
terminal complement cascade, however, the latter still
allowing for the formation of functional C5a.
Our in vitro ﬁndings of complement-induced
neutrophil adhesion to ECs were conﬁrmed in an
in vitro/ex vivo study using serum from 5 patients with
aHUS. Under ﬂow conditions, neutrophil adhesion was
observed in all patients. Although the effect was small
in the 2 patients treated with the terminal complement
blocker eculizumab (patients 4 and 5), neutrophil
adhesion was signiﬁcantly (up to 6-fold) increased in
patients without speciﬁc treatment (patient 1) and the 2
patients with plasma infusion treatment (patients 2 and
3). As previously established, when testing serum of a
patient with aHUS with a CFH mutation (c.3572C>T
[p.Ser1191Leu]) who was ﬁrst treated with plasma in-
fusions and subsequently with eculizumab,21 plasma
infusion achieves only partial (terminal) complement
blockade and is inferior to eculizumab. This difference
in treatment efﬁcacy may account for the difference in
EC neutrophil adhesion when comparing not treated
(patient 1), plasma-treated (patients 2 and 3), and
eculizumab-treated (patients 4 and 5) patients. Our
ﬁndings not only support a key role for the terminal
complement pathway in neutrophil adhesion to ECs,
but also suggest that neutrophil adhesion can be used
in an in vitro/ex vivo system using patient serum,
neutrophils, and control ECs to monitor disease activity
and treatment response, respectively, in patients with
aHUS.
Our ﬁndings are in keeping with a recently
published study by Noris et al.31, who investigated71
Figure 4. BOEC-adherent neutrophils promote platelet adhesion. (a–e) BOECs with combined incubation with anti-CD46, -CD55, and -CD59
antibodies were exposed to 50% NHS and either calcein-labeled platelets alone (upper channel) or labeled neutrophils and platelets together
(lower channel). In this typical experiment, bright neutrophil-platelet aggregates can be observed (original magniﬁcation 4) to develop and
increase in size over 6 (a), 12 (b), 20 (c), 30 (d), and 40 minutes (e). Bar ¼ 50 mm. Note: Adhesion of single platelets was not detectable at the
detector intensity setting used for these experiments. (f) A higher magniﬁcation (original magniﬁcation 20) image shows that aggregates
contain both platelets and neutrophils (small and large cells, respectively). Bar ¼ 20 mm. BOECs, blood outgrowth endothelial cells; NHS, normal
human serum.
TRANSLATIONAL RESEARCH M Riedl et al.: Complement and Neutrophils on Endothelial CellsMAC/C5b-9 deposition on ECs using serum samples
from patients with aHUS collected at different stages of
disease activity and treatment. MAC/C5b-9 deposition
on ECs was enhanced with serum of nontreated, but72suppressed with serum of eculizumab-treated pa-
tients. In a subgroup of patients with incomplete
complement control, however, MAC/C5b-9 deposition
on ECs was not fully suppressed, a ﬁnding thatKidney International Reports (2017) 2, 66–75
M Riedl et al.: Complement and Neutrophils on Endothelial Cells TRANSLATIONAL RESEARCHcorrelated with clinical signs of aHUS ﬂare-ups in these
patients.31
As TMA is a disease characterized by thrombus
formation in the microvasculature, we next investi-
gated if complement-mediated neutrophil adhesion to
ECs had a functional consequence with respect to
thrombus formation. Neutrophils were reported to
capture platelets causing lethal vascular occlusions, the
production of reactive oxygen species, and damage to
ECs in a mouse model of transfusion-related lung
injury.32 Also, on activation, platelets express several
surface molecules, which allow them to interact with
other cells, for example, neutrophils or ECs.33 In pre-
vious studies of the role of complement and platelets in
the pathogenesis of TMA, Licht et al.34 showed that
normal washed platelets aggregate in the absence of
serum because CFH autoantibodies induced functional
CFH deﬁciency. Finally, in a mouse model of Shiga
toxin-induced TMA, Morigi et al.35 were able to link
complement activation—induced by Shiga toxin and
lipopolysaccharides—to P-selectin upregulation and
thrombus formation on ECs.
To study the consequences of complement-mediated
neutrophil adhesion for platelet adhesion and aggre-
gation, we perfused a microﬂuidic chamber simulta-
neously with serum and isolated neutrophils and
platelets, devoid of coagulatory factors, which are
known to enhance complement activation on their
own.36 Interestingly, perfusion of platelets in combi-
nation with neutrophils in physiological concentrations
resulted in the formation of platelet-neutrophil aggre-
gates. These aggregates increased in size over time (40-
minute observation period) by recruiting more neu-
trophils and platelets and may represent microthrombi
in a system with an intact coagulation system.
In summary, our results show that complement
activation on ECs results in neutrophil adhesion, under
both static and microﬂuidic conditions. Neutrophil
adhesion is complement-mediated and terminal
pathway dependent. Neutrophil adhesion serves as
nidus for the formation of neutrophil-platelet aggre-
gates. Taken together, our ﬁndings strongly point to-
ward a key role for neutrophils in the pathogenesis of
complement-mediated TMA.
Statistical Analysis
Data are expressed as means  SD. Data were analyzed
using Graphpad Prism 7 (GraphPad Software Inc, La
Jolla, CA). Statistical tests were used as stated (mainly
paired t-test and 1-way analysis of variance). A P
value < 0.05 was considered statistically signiﬁcant.
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SUPPLEMENTARY MATERIAL
Figure S1. Calcein did not activate neutrophils. Using
ﬂowcytometry, no change in neutrophil CD11b expression
was observed after exposure to 30 minutes of calcein. (A)
Histogram shows the ﬂuorescent intensity for the following
conditions: unstained (gray line), positive control TNF-a (40
ng/ml for 30 minutes, gray dotted line), neutrophil in media
(black line) and neutrophils pretreated with calcein (2.5 mM,
black dotted line). A summary of three experiments is
shown in (B). Pretreatment with TNF-a (40 ng/ml) resulted
in a signiﬁcant (**P < 0.01) increase of CD11b.
Figure S2. Neutrophil adhesion to BOECs was
complement-mediated and terminal pathway dependent.
Neutrophil adhesion to BOECs following combined anti-
CD46, anti-CD55, and anti-CD59 antibody incubation
dropped to background levels when using heat-inactivated
serum (complement depleted) or when using C5-depleted
serum (terminal-pathway inactive). A summary of the re-
sults can be found in Figures 2b, d, and f.
Video S1. Neutrophil adhesion to BOECs is complement-
mediated. Calcein-labeled neutrophils perfused in a Bio-
ﬂux system at 1 dyne/cm2 over BOECs treated with
anti-CD46, anti-CD55, and anti-CD59 antibodies (upper and
bottom channel) and exposed to either NHS (bottom
channel) or complement inactive serum (HIS, upper
channel) showed marked neutrophil adhesion in the
presence of complement. Video starts 20 seconds after
ﬁrst neutrophils were observed in channel.
Video S2. Neutrophil adhesion to BOECs is terminal
pathway dependent. Calcein-labeled neutrophils perfused
in a Bioﬂux system at 1 dyne/cm2 in NHS (bottom channel)
or C5 depleted serum (upper channel) were exposed over
BOECs with anti-CD46, anti-CD55, and anti-CD59 antibody
pretreatment (upper and bottom channel). Neutrophil
adhesion was reduced when C5 depleted serum was used.73
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observed in channel.
Video S3. Neutrophils adhering to complement-challenged
BOECs initiate the formation of neutrophil-platelet aggre-
gates. BOECs with combined anti-CD46, anti-CD55, and
anti-CD59 antibody treatment were exposed to 50% NHS
and either calcein-labeled platelets alone (upper channel)
or labeled neutrophils and platelets together (lower chan-
nel). Perfusion of both resulted in formation of neutrophil-
platelet-aggregates. Video sequence start 90 seconds after
ﬁrst neutrophils/platelets were observed in channel.
Supplementary material is linked to the online version of
the paper at www.kireports.org.REFERENCES
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